Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.
GILD.MX
Strong BuyGilead Sciences, Inc. · Healthcare · United States · $181.0B · Avg Vol: $298K/d
85
StockRankGet insider-trade alerts
Q
59
V
55
M
67
P/E (TTM)
—
ROE
-20.7%
D/E
2.2x
Dividend %
2.2%
COMPANY DESCRIPTION
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
FINANCIAL SUMMARY (MXN)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 464.5B | 461.7B | 489.6B | 501.3B | 2.6% | 518.6B | 522.6B | 556.7B | 5.4% |
| EPS (MXN) | 62.32 | 77.31 | 6.47 | 116.47 | 23.2% | -45.11 | — | — | — |
| Shares | 1.2B | 1.2B | 1.2B | 1.2B | -0.5% | 1.2B | — | — | — |
| Debt | 429.6B | 425.5B | 454.8B | 424.6B | -0.4% | 446.9B | — | — | — |
| Equity | 361.7B | 388.8B | 329.2B | 386.6B | 2.2% | — | — | — | — |
| Op CF | 154.5B | 136.3B | 184.4B | 170.6B | 3.4% | 230.8B | — | — | — |
| Inv CF | -42.0B | -38.6B | -58.7B | -81.6B | — | — | — | — | — |
| Fin CF | -110.2B | -87.3B | -58.5B | -131.9B | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+2.9%
SMA 50SMA 200
Close
$145.06
RSI (14)
79.0
52W High
$153.68
From 52W High
0.9%
SCORE BREAKDOWN
Quality
59
ROIC
-2.0%44.2
ROE
-20.7%31.3
GP/Assets
41.1%80.0
Op. Margin
33.7%93.2
FCF/Assets
21.9%96.5
Piotroski
894.5
Int. Cover
-1.0x35.8
D/E Ratio
2.23x5.0
Current Ratio
1.26x19.0
Value
55
P/E (TTM)
—N/A
EV/EBITDA
12.8x55.8
P/FCF
14.0x73.1
P/B
0.9x86.1
P/S
6.1x37.1
Div Yield
2.2%50.6
Momentum
67
52W High %
94%90.6
RS 6M
9%71.4
SMA 50/200
0.99x57.3
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$181.0B
P/E (Forward)
—
Gross Margin
79.6%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of GILD.MX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| GILD.MX | Gilead Sciences, Inc.(you) | $181.0B | 85 | Strong Buy |
| PFE.DE | Pfizer Inc. | $158.9B | 88 | Strong Buy |
| NVO | Novo Nordisk A/S | $201.6B | 88 | Strong Buy |
| AMGN | Amgen Inc. | $233.8B | 89 | Strong Buy |
| NOVN.SW | Novartis AG | $299.9B | 86 | Strong Buy |
| GSK | GSK plc | $101.8B | 86 | Strong Buy |
| AZN | AstraZeneca PLC | $252.3B | 77 | Buy |
| RO.SW | Roche Holding AG | $372.5B | 86 | Strong Buy |
| SAN.PA | Sanofi | $109.4B | 94 | Strong Buy |
| BMY | Bristol-Myers Squibb Company | $136.0B | 99 | Strong Buy |
Peer medians: ROE 2.0% · P/E 24.0x · Gross margin 52.1%